Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 10, 2021

SELL
$5.94 - $8.75 $763,135 - $1.12 Million
-128,474 Closed
0 $0
Q2 2021

Aug 11, 2021

SELL
$7.54 - $9.79 $287,115 - $372,793
-38,079 Reduced 22.86%
128,474 $1.03 Million
Q1 2021

May 12, 2021

BUY
$4.76 - $11.25 $46,529 - $109,968
9,775 Added 6.23%
166,553 $1.61 Million
Q4 2020

Feb 10, 2021

BUY
$2.43 - $5.42 $69,986 - $156,101
28,801 Added 22.5%
156,778 $757,000
Q3 2020

Nov 13, 2020

SELL
$2.3 - $3.72 $11,596 - $18,756
-5,042 Reduced 3.79%
127,977 $319,000
Q2 2020

Aug 12, 2020

SELL
$1.33 - $3.63 $192,424 - $525,188
-144,680 Reduced 52.1%
133,019 $412,000
Q1 2020

May 14, 2020

SELL
$1.27 - $2.33 $290,507 - $532,978
-228,746 Reduced 45.17%
277,699 $400,000
Q4 2019

Feb 12, 2020

BUY
$1.3 - $2.72 $494,834 - $1.04 Million
380,642 Added 302.57%
506,445 $1.03 Million
Q3 2019

Nov 12, 2019

BUY
$1.93 - $4.21 $3,995 - $8,714
2,070 Added 1.67%
125,803 $296,000
Q2 2019

Aug 09, 2019

SELL
$2.05 - $4.32 $325,472 - $685,873
-158,767 Reduced 56.2%
123,733 $534,000
Q1 2019

May 15, 2019

BUY
$1.79 - $3.12 $22,251 - $38,784
12,431 Added 4.6%
282,500 $593,000
Q4 2018

Feb 14, 2019

BUY
$2.24 - $3.9 $111,088 - $193,412
49,593 Added 22.49%
270,069 $694,000
Q3 2018

Nov 13, 2018

SELL
$3.58 - $4.9 $10,664 - $14,597
-2,979 Reduced 1.33%
220,476 $858,000
Q2 2018

Aug 14, 2018

SELL
$4.43 - $5.14 $258,397 - $299,811
-58,329 Reduced 20.7%
223,455 $1.06 Million
Q1 2018

May 15, 2018

SELL
$4.65 - $5.9 $74,260 - $94,223
-15,970 Reduced 5.36%
281,784 $1.47 Million
Q4 2017

Feb 14, 2018

BUY
$4.32 - $5.52 $385,365 - $492,411
89,205 Added 42.77%
297,754 $1.38 Million
Q3 2017

Nov 14, 2017

BUY
$4.35 - $5.25 $907,188 - $1.09 Million
208,549
208,549 $1.1 Million

Others Institutions Holding CMRX

About CHIMERIX INC


  • Ticker CMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,622,896
  • Market Cap $85M
  • Description
  • Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...
More about CMRX
Track This Portfolio

Track Panagora Asset Management Inc Portfolio

Follow Panagora Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Panagora Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Panagora Asset Management Inc with notifications on news.